225 related articles for article (PubMed ID: 8697398)
1. Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
Schauenstein E; Lahousen M; Weblacher M; Steinschifter W; Estelberger W; Schauenstein K
Cancer; 1996 Aug; 78(3):511-6. PubMed ID: 8697398
[TBL] [Abstract][Full Text] [Related]
2. [Quantitative changes in the immunoglobulin G subclass system--a reliable tumor marker in squamous epithelial carcinoma in the area of the head-neck].
Anderhuber W; Steinschifter W; Gotschuli A; Schauenstein E; Schauenstein K
Laryngorhinootologie; 1998 Oct; 77(10):564-8. PubMed ID: 9842520
[TBL] [Abstract][Full Text] [Related]
3. Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue.
Schauenstein E; Rabl H; Steinschifter W; Hirschmann C; Estelberger W; Schauenstein K
Cancer; 1997 Apr; 79(8):1482-6. PubMed ID: 9118027
[TBL] [Abstract][Full Text] [Related]
4. The IgG1/G2 subclass shift--a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck.
Anderhuber W; Steinschifter W; Schauenstein E; Gotschuli A; Habermann W; Fischer M; Felsner P; Schauenstein K
Br J Cancer; 1999 Apr; 79(11-12):1777-81. PubMed ID: 10206292
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis: tumor marker].
Inaba N; Takamizawa Y; Ota J; Fukazawa K
Gan No Rinsho; 1990 Aug; 36(10):1123-7. PubMed ID: 2214148
[TBL] [Abstract][Full Text] [Related]
6. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies.
Miura N; Kanamori Y; Takahashi M; Sato R; Tsukamoto T; Takahashi S; Harada T; Sano A; Shomori K; Harada T; Kigawa J; Ito H; Terakawa N; Hasegawa J; Shiota G
Oncol Rep; 2007 Mar; 17(3):541-8. PubMed ID: 17273731
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
8. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
9. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
10. [Tissue polypeptide antigen as a tumor marker for gynecologic malignancies].
Inoue M; Fujita Y; Abe Y; Inoue Y; Ueda G; Tanizawa O; Minagawa J; Yamada T; Ohashi K; Ozaki M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1799-805. PubMed ID: 4056529
[TBL] [Abstract][Full Text] [Related]
11. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic significance of tumor markers for gynecologic malignancies].
Aoki D; Hirasawa A; Susumu N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
14. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
15. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
16. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of sialic acid determinations in patients with gynecologic cancer].
Shimizu Y; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Kurachi K; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jan; 39(1):49-55. PubMed ID: 3819514
[TBL] [Abstract][Full Text] [Related]
18. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of squamous cell carcinoma antigen (SCC-A) in Egyptian gynecologic cancer patients.
Salman T; el-Ahmady O; Tony O; Darwish M
Anticancer Res; 1997; 17(4B):3083-6. PubMed ID: 9329607
[TBL] [Abstract][Full Text] [Related]
20. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]